Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10063004	
Filing Date		2002-03-11	
First Named Inventor	Thom	nas Paul Feist	
Art Unit		1773	
Examiner Name	K. Be	ernatz	
Attorney Docket Numb	er	08CN8803-26	

				Attorney	DUC	ket Number		U8UN8803-26			
					J.S.I	PATENTS				Remove	_
Examiner Initial*	Cite No Patent Number Kind Code ¹			Issue Date	Issue Date Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	5609990		1997-03-11	1	Ha et al					
	2	6055140		2000-04-25	5	Marchon					
If you wish	to ac	id additional U.S. Pate	nt citatio	n informatio	on pi	ease click the	Ad	id button.		Add	_
			U.S.P	ATENT AP	PLI	CATION PUB	LIC	ATIONS		Remove	_
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	d Publication de ¹ Date		Name of Patentee or Applicant of cited Document		Relev	s,Columns,Lines where ant Passages or Relev ss Appear		
	1										
If you wish	n to ac	l dd additional U.S. Publi	shed Ap	plication cit	tation	information p	plea	ase click the Add	i buttor	n. Add	_
				FOREIGN	PAT	ENT DOCUM	IEN	ITS		Remove	_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		nd ode4	Publication Date	A	lame of Patented pplicant of cited locument	or	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1										Е
lf you wish	to a	dd additional Foreign P							button		_
			NON	-PATENT	LITE	RATURE DO	CU	JMENTS		Remove	

		Application Number		10063004		
	INFORMATION DIOCI COURT	Filing Date		2002-03-11		
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Thor		mas Paul Feist		
		Art Unit		1773		
		Examiner Name K. B		Bernatz		
		Attorney Docket Numb	er	08CN8803-26		

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5	
	1			

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPT/D Patent Documents at year USPT/D_COV or NEPP 901.04. ² Enter office that issued the document, by the bro-bitter code (NIPO Standard ST.3). ² Sort planetee patent concurrents, the action of the year of the Emperor must procede the sent number of the section counters. It was closed not be of the Emperor must procede the sent number of the section counters. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁵ Applicant is to place a check mark their of English languages the relatation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10063004
Filing Date		2002-03-11
First Named Inventor	Thon	nas Paul Feist
Art Unit		1773
Examiner Name	K. Be	matz
Attorney Docket Numb	er	08CN8803-26

CERTIFICATION STATEMENT

Please see	37 (CFR :	1 97	and :	1 98	to make	the	appropriate	selection(s)	

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information siclosure statement. See 37 CFR 197(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inequiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Pamela J. Curbelo/	Date (YYYY-MM-DD)	2006-08-29
Name/Print	Pamela J. Curbelo	Registration Number	34676

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 Card 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. O. Bast 1450, Alexandria, V.S.2311-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient of the patient application or patient. If you do not furnish the requested related to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may related that the patient process and/or examine your submission.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application port to public insepticines or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.